Compare Charles River Laboratories Intl. Inc (CRL) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Fox Corp Class B — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Fox Corp Class B trades at $55.42 (market cap $24.58B). The key difference: Fox Corp Class B is the larger of the two by market cap, and Fox Corp Class B pays a 1.05% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | FOX | |
|---|---|---|
Market Cap | $13.46B | $24.58B |
Sector | Health | Media |
52-Week High | $282.00 | $67.76 |
52-Week Low | $145.57 | $44.39 |
Enterprise Value | $16.30B | $27.94B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
FOX Corp trades at $55.99, down 0.6% with bullish technical signals and strong fundamental performance. The company reported robust Q2 2026 earnings of $1.79 EPS, beating expectations by 24%, with revenue growth accelerating to $16.3B in 2025. Analyst sentiment remains mixed with 43% buy ratings, while technical indicators show support at $54-55 levels with moving averages trending upward.
Outlook remains positive with digital growth momentum from Tubi and FOX One driving advertising revenue. Key risks include advertising market volatility and competitive pressures. The stock presents value opportunity with reasonable P/E of 14.4x and strong cash flow generation, though investors should monitor Q3 2026 earnings delivery against $2 EPS expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
